Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_Newton_Capital.jpeg10002267Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-15 08:26:202024-04-04 16:47:46Newton Biocapital launches new NBC III fund
European investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris.
https://european-biotechnology.com/wp-content/uploads/2024/04/EB_piggy-bank-g0355543d7_1280-pixabay.jpeg7681280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-13 17:11:002024-04-04 16:47:47New funds to boost European life sciences
AiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
Laurence Riot Lamotte has started at the beginning of 2022 als new Chief Financial Officer of French Diaccurate. She succeeds José Da Gloria, who left the company.
https://european-biotechnology.com/wp-content/uploads/2024/04/EIB.jpg535980Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2022-02-09 12:12:142024-04-04 16:47:49EU Council confirms European Scale-up Initiative
Co-founder and former board member of Galapagos NV Dr Paul Stoffels will take over the position of Chief Executive Officer at the Belgian company from April. He succeeds long-time CEO Onno van de Stolpe, who is retiring.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2022-02-08 09:30:172024-07-18 14:24:29New CEO for Galapagos
Centauri Therapeutics starting with £24m financing
Latest NewsAntimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics in US$1.7bn deal with MSD
Latest NewsCurve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital launches new NBC III fund
Latest NewsNewton Biocapital has launched a new life sciences fund with initial capital commitments of €50m and a target size of €150m.
New funds to boost European life sciences
Latest NewsEuropean investment firm LSP has closed its European life sciences fund LSP at €1 bn. Additionally, a €10bn fund of funds was greenlighted at the EU Council in Paris.
Aicuris licences antisense RNA know-how from Hybridize Therapeutics
Latest NewsAiCuris will pay up to €100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
Solid financial experience for Diaccurate
AppointmentsLaurence Riot Lamotte has started at the beginning of 2022 als new Chief Financial Officer of French Diaccurate. She succeeds José Da Gloria, who left the company.
BioNTech collaborates with AGC Biologics
Latest NewsAGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription.
EU Council confirms European Scale-up Initiative
Latest NewsEU Members States agreed on Tuesday to launch the pan-European Scale-up Initiative, which is aimed to provide €10bn for late-state tech companies.
Protix raises €50m for expansion
Latest NewsDutch insect protein specialist Protix has raised €50m for expansion and development from international investors and the ECBF.
New CEO for Galapagos
AppointmentsCo-founder and former board member of Galapagos NV Dr Paul Stoffels will take over the position of Chief Executive Officer at the Belgian company from April. He succeeds long-time CEO Onno van de Stolpe, who is retiring.